YILMAZ, N. Et Al. 2016. Malignanacy risk in scleroderma patients treated with cyclophosphamide. 4th Systemic Sclerosis World Congress , (LİZBON, Portugal).

YILMAZ, N., EMMUNGİL, H., GÜCENMEZ, S., ÖZEN, G., YILDIZ, F., BALKARLI, A., ... KİMYON, G.(2016). Malignanacy risk in scleroderma patients treated with cyclophosphamide . 4th Systemic Sclerosis World Congress, LİZBON, Portugal

YILMAZ, NESLİHAN Et Al. "Malignanacy risk in scleroderma patients treated with cyclophosphamide," 4th Systemic Sclerosis World Congress, LİZBON, Portugal, 2016

YILMAZ, NESLİHAN Et Al. "Malignanacy risk in scleroderma patients treated with cyclophosphamide." 4th Systemic Sclerosis World Congress , LİZBON, Portugal, 2016

YILMAZ, N. Et Al. (2016) . "Malignanacy risk in scleroderma patients treated with cyclophosphamide." 4th Systemic Sclerosis World Congress , LİZBON, Portugal.

@conferencepaper{conferencepaper, author={NESLİHAN YILMAZ Et Al. }, title={Malignanacy risk in scleroderma patients treated with cyclophosphamide}, congress name={4th Systemic Sclerosis World Congress}, city={LİZBON}, country={Portugal}, year={2016}}